Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $170426.0.

  • China Pharma Holdings' Accumulated Expenses fell 8642.57% to $170426.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $170426.0, marking a year-over-year decrease of 8642.57%. This contributed to the annual value of $247159.0 for FY2024, which is 1729.08% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Accumulated Expenses is $170426.0, which was down 8642.57% from $191293.0 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Accumulated Expenses registered a high of $1.3 million during Q3 2024, and its lowest value of $110387.0 during Q2 2022.
  • Moreover, its 5-year median value for Accumulated Expenses was $195264.0 (2025), whereas its average is $256629.3.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 94914.89% in 2024, then plummeted by 8642.57% in 2025.
  • Over the past 5 years, China Pharma Holdings' Accumulated Expenses (Quarter) stood at $298452.0 in 2021, then skyrocketed by 35.64% to $404807.0 in 2022, then decreased by 26.18% to $298829.0 in 2023, then decreased by 17.29% to $247159.0 in 2024, then tumbled by 31.05% to $170426.0 in 2025.
  • Its Accumulated Expenses was $170426.0 in Q3 2025, compared to $191293.0 in Q2 2025 and $195264.0 in Q1 2025.